Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse-Reference-Cited by-同舟云学术

Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse

Published:2019-01-28 Issue:8 Volume:60 Page:1890-1898
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Goldschmidt Neta¹,Horowitz Netanel A.²,Heffes Vered²,Darawshy Fares¹,Mashiach Tatiana³,Shaulov Adir¹,Gatt Moshe E.¹,Dann Eldad J.²⁴⁵

Affiliation:

1. Hematology Department, Hadassah-Hebrew University Medical School, Jerusalem, Israel;

2. Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;

3. Quality Assurance Unit, Rambam Health Care Campus, Haifa, Israel;

4. Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel;

5. Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1564823

Reference21 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

3. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

4. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper;British Journal of Haematology;2024-08-11

2. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures;World Neurosurgery;2023-11

3. Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse;Hematological Oncology;2023-06-29

4. Diffuse large B‐cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high‐dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis;American Journal of Hematology;2023-05-10

5. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis;Journal of Cancer;2023